Free Trial
NASDAQ:GALT

Galectin Therapeutics (GALT) Stock Price, News & Analysis

Galectin Therapeutics logo
$2.51 +0.06 (+2.45%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$2.56 +0.05 (+1.99%)
As of 07/11/2025 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Galectin Therapeutics Stock (NASDAQ:GALT)

Key Stats

Today's Range
$2.43
$2.64
50-Day Range
$1.24
$3.29
52-Week Range
$0.73
$3.90
Volume
391,063 shs
Average Volume
415,829 shs
Market Capitalization
$158.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Buy

Company Overview

Galectin Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

GALT MarketRank™: 

Galectin Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 659th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Galectin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Galectin Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Galectin Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.73) to ($0.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Galectin Therapeutics is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Galectin Therapeutics is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Galectin Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    17.94% of the float of Galectin Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Galectin Therapeutics has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Galectin Therapeutics has recently decreased by 12.96%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Galectin Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Galectin Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.94% of the float of Galectin Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Galectin Therapeutics has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Galectin Therapeutics has recently decreased by 12.96%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Galectin Therapeutics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Galectin Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for GALT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Galectin Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    50.10% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 11.68% of the stock of Galectin Therapeutics is held by institutions.

  • Read more about Galectin Therapeutics' insider trading history.
Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GALT Stock News Headlines

Galectin Therapeutics Inc. (GALT) - Yahoo Finance
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
Galectin Therapeutics Inc.
See More Headlines

GALT Stock Analysis - Frequently Asked Questions

Galectin Therapeutics' stock was trading at $1.29 at the start of the year. Since then, GALT shares have increased by 94.6% and is now trading at $2.51.

Galectin Therapeutics Inc. (NASDAQ:GALT) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.05.

Galectin Therapeutics' top institutional investors include Sovran Advisors LLC (0.30%). Insiders that own company stock include James C Czirr, Joel Lewis, Kary Eldred, Richard A Jr Zordani, Kevin D Freeman, Khurram Jamil, Harold H Shlevin and Jack W Callicutt.
View institutional ownership trends
.

Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galectin Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/15/2025
Today
7/12/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GALT
CIK
1133416
Employees
9
Year Founded
N/A

Price Target and Rating

High Price Target
$6.00
Low Price Target
$6.00
Potential Upside/Downside
+139.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$47.05 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-216.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.08
Quick Ratio
0.08

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.68) per share
Price / Book
-1.49

Miscellaneous

Outstanding Shares
63,290,000
Free Float
31,583,000
Market Cap
$158.86 million
Optionable
Optionable
Beta
0.70

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:GALT) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners